Dallmann I - Search Results

1

Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.

Atzpodien J, Kirchner H, Körfer A, Hadam M, Schomburg A, Menzel T, Deckert M, Franzke A, Volkenandt M, Dallmann I, et al. Atzpodien J, et al. Among authors: dallmann i. Tumour Biol. 1993;14(6):354-9. doi: 10.1159/000217850. Tumour Biol. 1993. PMID: 8265981

2

In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.

Schomburg A, Menzel T, Körfer A, Heer G, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J. Schomburg A, et al. Among authors: dallmann i. Nat Immun. 1992 May-Jun;11(3):133-43. Nat Immun. 1992. PMID: 1392401

3

Diminished expression of interleukin-2 receptors in vivo after prior chemotherapy in advanced cancer patients receiving recombinant interleukin-2.

Atzpodien J, Körfer A, Hadam M, Schomburg A, Menzel T, Dallmann I, Poliwoda H, Kirchner H. Atzpodien J, et al. Among authors: dallmann i. Mol Biother. 1991 Jun;3(2):60-2. Mol Biother. 1991. PMID: 1910621

4

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.

Hänninen EL, Körfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, Kirchner H, Poliwoda H, Atzpodien J. Hänninen EL, et al. Among authors: dallmann i. Cancer Res. 1991 Dec 1;51(23 Pt 1):6312-6. Cancer Res. 1991. PMID: 1933892

5

Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.

Atzpodien J, Körfer A, Evers P, Franks CR, Knüver-Hopf J, Lopez-Hänninen E, Fischer M, Mohr H, Dallmann I, Hadam M, et al. Atzpodien J, et al. Among authors: dallmann i. Mol Biother. 1990 Mar;2(1):18-26. Mol Biother. 1990. PMID: 2334534

6

Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.

Schneekloth C, Körfer A, Hadam M, Lopez Hänninen E, Menzel T, Schomburg A, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J. Schneekloth C, et al. Among authors: dallmann i. Acta Haematol. 1993;89(1):13-21. doi: 10.1159/000204476. Acta Haematol. 1993. PMID: 7683166

7

In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2.

Meffert M, Hanninen EL, Menzel T, Schomburg A, Duensing S, Dallmann I, Grosse J, Vocke S, Buer J, Deckert M, et al. Meffert M, et al. Among authors: dallmann i. Cancer Biother. 1994 Winter;9(4):307-16. doi: 10.1089/cbr.1994.9.307. Cancer Biother. 1994. PMID: 7719378 Clinical Trial.

8

In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.

Meffert M, Schomburg A, Hänninen EL, Menzel T, Vocke S, Dallmann I, Grosse J, Duensing S, Buer J, Kirchner H, et al. Meffert M, et al. Among authors: dallmann i. Anticancer Res. 1995 Jan-Feb;15(1):127-32. Anticancer Res. 1995. PMID: 7733621

9

Clinical and preclinical evaluation of recombinant PEG-IL-2 in human.

Menzel T, Schomburg A, Körfer A, Hadam M, Meffert M, Dallmann I, Casper S, Kirchner H, Poliwoda H, Atzpodien J. Menzel T, et al. Among authors: dallmann i. Cancer Biother. 1993 Fall;8(3):199-212. doi: 10.1089/cbr.1993.8.199. Cancer Biother. 1993. PMID: 7804360 Clinical Trial.

10

Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus.

Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Zorn U, et al. Among authors: dallmann i. Cancer Biother. 1994 Fall;9(3):225-35. doi: 10.1089/cbr.1994.9.225. Cancer Biother. 1994. PMID: 7820184

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters